Targeted therapy comes of age in scleroderma.
Systemic sclerosis (SSc, also known as scleroderma) has the highest case-specific mortality among the rheumatic diseases; however, advances in understanding of pathogenesis and an appreciation of the clinical heterogeneity of this disease, together with therapeutic advances in other areas, have raised the possibility of substantial improvements in its management. Key areas of advance include the development of clinical and laboratory methods for early detection of complications and the integration of vascular, immunomodulatory and antifibrotic therapies. Disease models have facilitated the identification of key mediators or processes that could be targeted therapeutically and have provided a platform for preclinical testing of novel candidate therapies. This review will consider current clinical aspects of SSc and the emergence of targeted therapy that is linked to key pathogenic processes or that targets pivotal mediators.
Denton
Christopher P
CP
Centre for Rheumatology, Royal Free Campus, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK. c.denton@medsch.ucl.ac.uk
Black
Carol M
CM
D000367:Age Factors; D018450:Disease Progression; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D007165:Immunosuppression Therapy; D018448:Models, Immunological; D012595:Scleroderma, Systemic / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*